These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Acute effects of verapamil on neuromuscular transmission in patients with myasthenia gravis. Lee SC; Ho ST Proc Natl Sci Counc Repub China B; 1987 Jul; 11(3):307-12. PubMed ID: 2827211 [TBL] [Abstract][Full Text] [Related]
5. The pharmacological basis for the treatment of myasthenia gravis. Flacke W Pharmacol Physicians; 1970 Jun; 4(6):1-7. PubMed ID: 4316342 [No Abstract] [Full Text] [Related]
6. Single-fiber electromyography during menstrual exacerbation and ovulatory suppression in MuSK antibody-positive myasthenia gravis. Stickler DE; Stickler LL Muscle Nerve; 2007 Jun; 35(6):808-11. PubMed ID: 17221882 [TBL] [Abstract][Full Text] [Related]
7. Benefit from alternate-day prednisone in myasthenia gravis. Warmolts JR; Engel WK N Engl J Med; 1972 Jan; 286(1):17-20. PubMed ID: 4331158 [No Abstract] [Full Text] [Related]
8. [Neurophysiological monitoring of the myasthenia patient during and after thymectomy (author's transl)]. Bergmans J Ann Chir; 1980 Mar; 34(3):182-7. PubMed ID: 6245617 [No Abstract] [Full Text] [Related]
9. [Mechanism of action of muscle relaxants and its clinical problems]. Suzuki H Masui; 1974 Aug; 23(8):679-92. PubMed ID: 4372420 [No Abstract] [Full Text] [Related]
10. The effect of cholinesterase inhibitors of SFEMG in myasthenia gravis. Massey JM; Sanders DB; Howard JF Muscle Nerve; 1989 Feb; 12(2):154-5. PubMed ID: 2540433 [TBL] [Abstract][Full Text] [Related]
11. Adverse drug effects on neuromuscular transmission. Howard JF Semin Neurol; 1990 Mar; 10(1):89-102. PubMed ID: 2161128 [No Abstract] [Full Text] [Related]
12. [Neuromuscular transmission in myasthenia gravis]. Takamori M; Tajima H; Sugimoto S; Tsujihata M Naika; 1968 Apr; 21(4):761-7. PubMed ID: 4302046 [No Abstract] [Full Text] [Related]
13. Correlation between a patient-derived functional questionnaire and abnormal neuromuscular transmission in Myasthenia Gravis patients. Rostedt A; Padua L; Stålberg EV Clin Neurophysiol; 2005 Sep; 116(9):2058-64. PubMed ID: 16043394 [TBL] [Abstract][Full Text] [Related]
14. [Clinical and pharmacological examination of neuromuscular transmission]. Defféminis Rospide HA; Scarabino R; Silva Gaudin E Acta Neurol Latinoam; 1969; 15(1):117-26. PubMed ID: 4329847 [No Abstract] [Full Text] [Related]
15. A reassessment of the neurophysiological evidence for a presynaptic defect in myasthenia gravis. Bergmans J; Fannes-Breselow CF; Gribomont B Electromyogr Clin Neurophysiol; 1976; 16(4):337-51. PubMed ID: 187402 [No Abstract] [Full Text] [Related]
16. [Neuromuscular transmission in patients with myasthenia gravis treated by plasmapheresis and hemosorption]. Marshaniia ZS; Sanadze AG; Kil'diushevskiĭ AV; Startsev AI Klin Med (Mosk); 1987 Jul; 65(7):107-10. PubMed ID: 2822998 [No Abstract] [Full Text] [Related]
17. [Single fiber electromyography in myasthenia gravis]. Chiu HC Taiwan Yi Xue Hui Za Zhi; 1988 May; 87(5):574-8. PubMed ID: 2843601 [No Abstract] [Full Text] [Related]
18. Neurophysiological aspects of diagnosis in neuromuscular transmission defects--an update. Stålberg E Electroencephalogr Clin Neurophysiol Suppl; 1999; 50():377-85. PubMed ID: 10689484 [No Abstract] [Full Text] [Related]
19. Plasma concentration and pharmacological effects of pyridostigmine in patients with myasthenia gravis [proceedings]. Calvey TN; Chan K Br J Clin Pharmacol; 1977 Jun; 4(3):404P. PubMed ID: 197984 [No Abstract] [Full Text] [Related]
20. Physiology of neuromuscular transmission. Roberts DV; Wilson A Physiotherapy; 1972 Aug; 58(8):277-9. PubMed ID: 4360596 [No Abstract] [Full Text] [Related] [Next] [New Search]